Health Canada has officially authorized the first generic version of the semaglutide injection that is specifically intended for weight loss.
The product from Canadian-based pharmaceutical company Apotex is known as Sevmia and serves as a generic alternative to Wegovy, the brand-name medication developed by Denmark’s Novo Nordisk.
“Health Canada authorized the drug after a thorough review of evidence provided by the company demonstrated that the drug meets Health Canada’s criteria for safety, efficacy and quality for generic drugs,” the federal agency said in a June 29 press release.
Svemia is designed for the weekly treatment of individuals 12 and older, as a complement to a reduced-calorie diet and increased physical activity aimed at chronic weight management, Health Canada said….